Synthesis, Structure-Activity Relationship, and Pharmacophore Modeling Studies of Pyrazole-3-Carbohydrazone Derivatives as Dipeptidyl Peptidase IV Inhibitors

Chemical Biology and Drug Design

Volumn 79, Issue 6, 2012, Pages 897-906

  Wu, Deyan ^a   Jin, Fangfang ^a   Lu, Weiqiang ^a   Zhu, Jin ^a   Li, Cui ^a   Wang, Wei ^a   Tang, Yun ^a   Jiang, Hualiang ^a,b   Huang, Jin ^a   Liu, Guixia ^a   Li, Jian ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Dipeptidyl peptidase IV; Inhibitors; Molecular docking; Pharmacophore modeling; Synthesis

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; N' [1 [2,4 DIHYDROXYPHENYL]ETHYLIDENE] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' [3,4 DIHYDRO 1[2H] NAPHTHALEN 1 YL] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' [[1 METHYL 1H PYRROL 2 YL]METHYLENE] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' [[2 HYDROXY NAPHTHALEN 1 YL]METHYLENE] 1,4,5,6 TETRAHYDRO CYCLOPENTA[C]PYRAZOLE 3 CARBOHYDRAZONE; N' [[2 HYDROXY NAPHTHALEN 1 YL]METHYLENE] 1,4,5,6,7,8 HEXAHYDRO CYCLOPENTA[C]PYRAZOLE 3 CARBOHYDRAZONE; N' [[2 HYDROXY NAPHTHALEN 1 YL]METHYLENE] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' [[2 HYDROXY NAPHTHALEN 1 YL]METHYLENE] 5 [3 METHOXYPHENYL] 1H PYRAZOLE 3 CARBOHYDRAZOLE; N' [[2 HYDROXY PHENYL]METHYLENE] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' [[2,4 DIHYDROXYPHENYL]METHYLENE] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' [[3 CHLORO 4 HYDROXY 5 METHOXYPHENYL]METHYLENE] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' [[4 CHLORO 3 FLUOROPHENYL]METHYLENE] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' [[4 CHLORO 3 NITROPHENYL]METHYLENE] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' [[4 CYANO PHENYL]METHYLENE] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' [[4 METHOXY NAPHTHALEN 1 YL]METHYLENE] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' [[NAPHTHALEN 1 YL]METHYLENE] 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; N' CYCLOHEPTYLIDENE 4,5,6,7 TETRAHYDRO 1H INDAZOLE 3 CARBOHYDRAZONE; PYRAZOLE 3 CARBOHYDRAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROGEN BOND; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

BINDING SITES; COMPUTER SIMULATION; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYDRAZONES; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INDAZOLES; NAPHTHALENES; PROTEIN STRUCTURE, TERTIARY; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862796538     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01365.x     Document Type: Article

References (17)

1. Gorrell M.D., Gysbers V., McCaughan G.W. (2001) CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol;54:249-264.
2. Meester I.D., Durinx C., Proost P., Scharpe S., Lambier A.M. (2002) Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in Medicine and Biology. New York: Kluwer Academic/Pleneu Publisher; pp. 223-257.
3. Mentlein R., Gallwitz B., Schmidt W.E. (1993) Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem;214:829-835.
4. Kieffer T.J., McIntosh C.H., Pederson R.A. (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology;358:5-3596.
5. Kim D., Wang L.P., Beconi M., Eiermann G.J., Fisher M.H., He H.B., Hickey G.J. et al. (2005) (2R)-4-Oxo-4-[3-(trifluoromethyl)-5, 6-dihydro[1, 2, 4]triazolo[4, 3-α]pyrazin-7(8H)-yl]-1-(2, 4, 5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem;48:141-151.
6. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., Hughes T.E. (2003) 1-[[(3-hydroxy-1-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem;46:2774-2789.
7. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A.Y. et al. (2005) Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem;48:5025-5037.
8. Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B., Navre M., Shi L., Skene R.J., Asakawa T., Takeuchi K., Xu R., Webb D.R., Gwaltney S.L. (2007) Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem;50:2297-2300.
9. Eckhardt M., Langkop E., Mark M., Tadayyon M., Thomas L., Nar H., Pfrengle W., Guth B., Lotz R., Sieger P., Fuchs H., Himmelsbach F. (2007) 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem;50:6450-6453.
10. Biftu T., Scapin G., Singh S., Feng D., Becker J.W., Eiermann G., He H. et al. (2007) Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. Bioorg Med Chem Lett;17:3384-3387.
11. Snyder H.R., Brooks L.A., Shapiro S.H. (1943) Pimelic acid. Org Synth;2:531.
12. van Herk T., Brussee J., van den Nieuwendijk A.M.C.H., van der Klein P.A.M., Ijzerman A.P., Stannek C., Burmeister A., Lorenzen A. (2003) Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem;46:3945-3951.
13. Kirchner F.K., Bethlehem N.Y. (1961) 1-(3-Indazolecarbonyl)-hydrazines and their preparation. Patent No. US3007938.
14. Demuth H.U., McIntosh C.H., Pederson R.A. (2005) Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta;1751:33-44.
15. Li C., Shen J., Li W.H., Lu C.H., Liu G.X., Tang Y. (2011) Possible ligand release pathway of dipeptidyl peptidase IV investigated by molecular dynamics simulations. Proteins;79:1800-1809.
16. Lu I.L., Tsai K.C., Chiang Y.K., Jiaang W.T., Wu S.H., Mahindroo N., Chien C.H., Lee S.J., Che X., Chao Y.S., Wu S.Y. (2008) A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Eur J Med Chem;43:1603-1611.
17. Zeng J., Liu G.X., Tang Y., Jiang H.L. (2007) 3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA. J Mol Model;13:993-1000.